Latest Healthcare News

Invion Limited has progressed its Photosoft clinical programs with new patient dosing and an expanded collaboration with Hanlim Pharm, backed by a successful $2 million share placement to accelerate development.

SomnoMed Limited reported a robust 23.2% revenue increase in Q3 FY25, reaffirming its full-year guidance while actively addressing new US tariffs through potential duty-free exemptions.

Hydralyte North America reported a 16% rise in Q1 FY25 net sales and improved gross margins, supported by a strategic capital raise and upcoming product launches targeting brain and gut health.

Imagion Biosystems has progressed its MagSense HER2 breast cancer imaging agent towards a pivotal Investigational New Drug application with the FDA, backed by a solid funding runway exceeding 13 quarters.

InteliCare Holdings reported a net operating cash outflow of AUD 447,000 for Q1 2025 but remains confident in sustaining operations through active cash management and potential capital raises.

Vectus Biosystems advances its lead fibrosis drug VB0004 with validated Phase I safety data and strategic cost reductions, while actively pursuing licensing partnerships in China.

TrivarX has launched a pivotal mental health clinical trial in partnership with the US Department of Veterans Affairs, leveraging its innovative ECG-based technology to screen for major depressive episodes. The company also secured $2.25 million in funding, positioning it for regulatory milestones ahead.

Cann Group Limited reported a 20% rise in Q3 production and improved operating cash flow, while navigating a 38% sales dip due to order timing. The company bolstered its balance sheet with new funding and expanded its Botanitech distribution network.

IMEXHS Limited reported modest revenue growth and a 16% increase in ARR in Q1 FY25, alongside the commercial rollout of its Aquila+ radiology platform and a $2.5 million capital raising to fuel expansion.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.